Final answer:
The claim that more than 20% of users develop nausea is supported by the data, as the p-value is less than the significance level.
Step-by-step explanation:
The p-value for testing the claim that more than 20% of users develop nausea is 0.0095, which is less than the significance level of 0.05. Therefore, we reject the null hypothesis and conclude that there is sufficient evidence to support the claim that more than 20% of users develop nausea. By rejecting the null hypothesis, we are stating that the observed proportion of users developing nausea is significantly different from the hypothesized proportion of 20%. In other words, the drug is causing a higher than expected rate of nausea among users. This decision is based on the principle of hypothesis testing, where we compare the p-value (the probability of obtaining a test statistic as extreme as the observed value) to the significance level (alpha) to determine whether to reject or fail to reject the null hypothesis.